Phase 2 N=17 Pharmacokinetic and Pharmacodynamic Study of Cyclofem
Contraception
Primary: Medroxyprogesterone Acetate (MPA) Concentrations — 0.00; 0.27; 0.43; 0.44 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)
Mycoses
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) by 12 Weeks or End of Treatment — 26; 46 Percentage of participants
Phase 3 N=290 Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis
Tinea Pedis
Primary: Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2) — 73; 10 participants
Phase 4 N=26 Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder
Severe Asthma · Moderate or Severe Major Depressive Disorder
Primary: HAM-D (Hamilton Rating Scale for Depression) — 24.8; 28.3 units on a scale
N/A N=106 Evaluation of Blood Glucose Meter Systems
Diabetes
Primary: MARD (Mean Absolute Relative Difference Between BGMS Results and Reference Method Results) Across the Overall Tested Glucose Range — 3.3; 4.9; 5.8; 10.7 Percent Difference
Phase 3 N=371 BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
Colon Cancer
Primary: Efficacy - Preparation Quality Using a 4 Point Scale — 94; 94 percentage of participants
Phase 2 N=40 Naloxone SR Capsules in Patients With Opioid Induced Constipation
Chronic Pain · Opioid Induced Constipation
Primary: Incidence and Severity of Treatment Emergent Adverse Events on Single Dosing. — 8; 5; 4; 6 participants
Phase 3 N=218 Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Type 2 Diabetes Mellitus · High HbA1c Level · Inadequate Glycaemic Control
Primary: Adjusted Mean Change From Baseline in HbA1c Levels — -0.17; -0.86 Percent — p=<0.0001
Phase 2 N=122 A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
Heart Failure, Congestive · Edema
Primary: Body Weight — -0.53; -1.62; -1.35; -1.85 Kg — p=0.0074
Phase 2 N=18 Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.
Pulmonary Hypertension
Primary: Maximum Change From Baseline in Supine Systolic Blood Pressure (SBP) Within 4 Hours Post-dose at Visit 6 (Week 12) — -20.70; -20.20 mmHg
Phase 2 N=11 Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders
Urea Cycle Disorders
Primary: Rate of Adverse Events During the Switchover Part of the Study Rate of Adverse Events (Number of Participants Showing Adverse Events) — 4; 2 participants
Phase 4 N=56 A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium
Pulmonary Disease, Chronic Obstructive
Primary: Variability in Daily FEV1, Estimated by Coefficient of Variation — 0.081; 0.079; 0.059; NA Liters
Phase 3 N=250 A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
Osteoporosis, Postmenopausal
Primary: Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6 — 4.26; 1.20 percent change — p=<0.0001
Phase 3 N=573 Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Abscess · Wound Infection · Surgical Site Infection
Primary: Early Clinical Efficacy — 240; 233; 48; 52 participants
N/A N=63 A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens
Myopia
Primary: Visual Acuity — -0.029; -0.043 logMAR